Clinical Research
Opportunities

Penn Medicine is conducting studies to develop new ways to prevent, diagnose, and treat disease. You might be eligible to participate

Penn Medicine is conducting studies to develop new ways to prevent, diagnose, and treat disease. You might be eligible to participate

Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.

Recently Added/Updated trials

 Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea on Sympathetic and Vascular Function

Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea on Sympathetic and Vascular Function

21 years - 99 years
All genders
The hypoglossal nerve controls tongue movement. The Inspire® sleep implant works by stimulating this nerve. This process is called hypoglossal nerve stimulation, or “HGNS.” In this study, we are interested in seeing how HGNS affects blood pressure and heart-related measures and if it lowers the risk of heart problems in people with obstructive sleep apnea.
 An Exploratory Case-Control Study of Genetic and Clinical Factors For Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate With New Medications taken for atleast 3 months prior to the study

An Exploratory Case-Control Study of Genetic and Clinical Factors For Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate With New Medications taken for atleast 3 months prior to the study

1 years - 100 years
Non-Binary
Eslicarbazepine acetate (Aptiom®) is an antiepileptic drug (AED) approved in the United States (US) as adjunctive therapy for the treatment of partial-onset seizures in adults .Prior research has shown that seizure medicines like carbamazepine (Tegretol®) and oxcarbazepine (Trileptal®, Oxtellar®) are more likely to cause severe drug related skin reactions in some people of Asian ancestry who have specific genes. These are genes found in an area of your chromosomes (packaging for your genes) called the Major Histocompatibility Complex. This association is called a genetic risk factor.
 UPCC#01409: Lintuzumab-Ac225 in Older Patients with Untreated AML

UPCC#01409: Lintuzumab-Ac225 in Older Patients with Untreated AML

99 years or below
All genders
This is a phase 1/2 study of a radio-labeled investigational drug, 225Ac-lintuzumab, given in combination with low-dose cytarabine in previously untreated elderly patients with AML. Phase 1 will establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside, and Phase 2 will help determine the response rate of these drugs in combination. We anticipate that between 10-15 subjects will participate in this study at UPenn.

Volunteer sign up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Healthy Volunteers

Currently seeking healthy volunteers for research studies.

Logo

CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.

View More